A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)

Diabetologia

Volumn 47, Issue 10, 2004, Pages 1747-1759

  Clarke, P M ^a,d   Gray, A M ^a   Briggs, A ^a   Farmer, A J ^b   Fenn, P ^c   Stevens, R J ^d   Matthews, D R ^d   Stratton, I M ^d   Holman, R R ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NOTTINGHAM UNIVERSITY BUSINESS SCHOOL   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Blood glucose; Diabetes; Diabetes related complications; Economic evaluation; Life expectancy; Quality adjusted life years; Risk equation simulation model; UKPDS

Indexed keywords

ADULT; AGED; AMPUTATION; ARTICLE; BLINDNESS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HEALTH ECONOMICS; HUMAN; KIDNEY DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; SIMULATION; TREATMENT OUTCOME;

AMPUTATION; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; FEMALE; GREAT BRITAIN; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 11144298966     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1527-z     Document Type: Article

References (36)

1. Eastman RC, Javitt JC, Herman WH et al. (1997) Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20:725-734
2. Brown JB, Russell A, Chan W, Pedula K, Aickin M (2000) The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 50 [Suppl 3]:S15-S46
3. Palmer AJ, Brandt A, Valerio G, Weiss C, Stock H, Wenzel H (2000) Outline of a diabetes disease management model. Principles and applications. Diabetes Res Clin Pract 50 [Suppl 3]:S47-S56
4. Bagust A, Hopkinson PK, Maier W, Currie CJ (2001) An economic model of the long-term health care burden of Type II diabetes. Diabetologia 44:2140-2155
5. CDC Group (2002) Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287:2542-2551
6. DCCT (1996) Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. JAMA 276:1409-1415
7. Yeo WW, Yeo KR (2001) Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18:341-344
8. UKPDS Group (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412
9. Adler AI, Stratton IM, Neil HA et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419
10. Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671-679
11. Kothari V, Stevens RJ, Adler AI et al. (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33:1776-1781
12. UKPDS Group (1991) UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877-890
13. UKPDS Group (1994) Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534-544
14. Hougaard P (2000) Analysis of multivariate survival data (Statistics for biology and health). Springer, Berlin
15. American Diabetes Association (1998) Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 21:296-309
16. Brown JB, Pedula KL, Bakst AW (1999) The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 159:1873-1880
17. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB (1991) Probability of stroke: a risk profile from the Framingham Study. Stroke 22:312-318
18. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG (1999) A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care 22:1036-1042
19. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ (1997) Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 278:2069-2074
20. UKPDS Group (2003) Development and progression of nephropathy in Type 2 diabetes: observation and modelling from the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225-232
21. Cupples LA, D'Agostino RB, Anderson K, Kannel WB (1988) Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Stat Med 7:205-222
22. Altman DG, De Stavola BL (1994) Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 13:301-341
23. Greene WH (1997) Econometric analysis, 4 edn. Prentice-Hall, London
24. UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
25. Panzram G (1987) Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:123-131
26. Wright JC, Weinstein MC (1998) Gains in life expectancy from medical interventions - standardizing data on outcomes. N Engl J Med 339:380-386
27. EuroQol Group (1990) EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16:199-208
28. Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22:340-349
29. Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19:453-473
30. Gray A, Raikou M, McGuire A et al. (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 320:1373-1378
31. Schafer JL (1999) Multiple imputation: a primer. Stat Methods Med Res 8:3-15
32. Government Actuary's Department (2003) Interim life tables 1999-2001. The Stationery Office, London
33. Williams R, Van Gaal L, Lucioni C (2002) Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 45:S13-S17
34. Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121:293-298
35. Menotti A, Lanti M, Puddu PE (2000) Long-term time-related predictivity of coronary events as a function of a single measurement of serum cholesterol and systolic blood pressure. Acta Cardiol 55:87-93
36. Stevens R, Adler A, Gray A, Briggs A, Holman R (2000) Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 50 [Suppl 3]:S5-S13